

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 October 2021 (28.10.2021)



(10) International Publication Number
WO 2021/213512 A1

(51) International Patent Classification:

A61K 31/506 (2006.01) *A61P 27/12* (2006.01)
A61P 27/06 (2006.01) *A61P 35/00* (2006.01)
A61P 27/10 (2006.01) *A61P 37/00* (2006.01)

(21) International Application Number:

PCT/CN2021/089415

(22) International Filing Date:

23 April 2021 (23.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/086647

24 April 2020 (24.04.2020)

CN

(71) Applicant: **GUANGZHOU KANGRUI BIOLOGICAL PHARMACEUTICAL TECHNOLOGY CO., LTD.** [CN/CN]; Room 502, 5th Floor, Phase I, RayBiotech Building, 79 Ruihe Road, Huangpu District, Guangzhou, Guangdong 510000 (CN).

(72) Inventors: **ZANG, Guangxi**; Room 502, 5th Floor, Phase I, RayBiotech Building, 79 Ruihe Road, Huangpu District, Guangzhou, Guangdong 510000 (CN). **LI, Gen**; Room 502, 5th Floor, Phase I, RayBiotech Building, 79 Ruihe Road, Huangpu District, Guangzhou, Guangdong 510000 (CN).

(74) Agent: **AFD CHINA INTELLECTUAL PROPERTY LAW OFFICE**; Tower B, 21st Fl., Suite 2108, 38 Xueqing Road, Haidian, Beijing 100083 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: A FORMULATION FOR TREATING OPHTHALMIC CONDITIONS

FIG. 4



(57) Abstract: A pharmaceutical composition for ophthalmic dosing or administration is disclosed, comprising (i) a compound of Formula (I) or an isotopic variant, tautomer, pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) at least one pharmaceutically acceptable excipient. The pharmaceutical composition is formulated as a suspension. The composition may be used to treat ophthalmic disorders and diseases caused by abnormal proliferation of angiogenesis.

WO 2021/213512 A1